JPMorgan extended Roivant Sciences (ROIV) as a top pick from 2025 to 2026 following the company’s investor day. The firm also added Roivant to its Analyst Focus List as a growth idea. JPMorgan has an Overweight rating on the shares with a $26 price target Roivant’s business structure “should stand out on its own.” the analyst tells investors in a research note. The firm says multiple catalysts” were pulled forward to 2026 across the company’s core Vants.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences Highlights Pipeline Progress at Investor Day
- Roivant Sciences highlights pipeline progress at Investor Day
- Moderna price target raised to $18 from $15 at Leerink
- Einhorn’s DME Capital bought PG&E and United Parks in Q3
- Roivant Sciences price target raised to $23 from $20 at H.C. Wainwright